65,437 trials
Dementia · Alzheimer's Disease
Primary: Number of Participants With Incident Dementia — 277; 246 Participants — p=0.21
Serious Fungal Infections
Primary: Percentage of Participants With Categorical Clinical Response: Cure, Improvement, Failure, or Unevaluable — 12.72; 41.47; 17.92; 27.89 percentage of participants
Idiopathic Pulmonary Arterial Hypertension · Cardiomyopathy
Primary: Number of Participants With Reversible Pulmonary Hypertension (Vasoreactivity) — 28; 16 Participants
Hematological Malignancies
Primary: Occurrences of Pneumonia — 4; 3 Participants
Glioblastoma Multiforme
Primary: Maximal Tolerating Dose (MTD for Phase I) — 3; 3; 6; 3 participants
Coronary Arteriosclerosis · Acute Coronary Syndromes
Primary: Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke — 469; 565; 174; 216…
Chronic Obstructive Pulmonary Disease
Primary: Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year — 0.75; 0.84; 1.14 Exacerbations
Heart Defects, Congenital · Heart Failure, Congestive
Primary: Weight-for-age Z-score at 14 Months of Age — -0.62; -0.42 standard deviation — p=0.28
Gastroesophageal Reflux Disease
Primary: Patient's Assessment of General Well-being During the Last 24 Hours (Diaries; ReQuest™ in Practice) — 5.31; 4.60; 3.67; 2.95 Units on a scale
Acute Coronary Syndrome
Primary: Maximum Platelet Aggregation (MPA) to 20 Micromolar (μM) Adenosine Diphosphate (ADP) — 27.1; 40.3 Percentage aggregation — p=<0.001
Hypertension
Primary: Trough Sitting Diastolic Blood Pressure — 81.3; 81.1; 1.8; 7.7 mm HG
Sleep Disorders · Non-Erosive Reflux Disease · Gastroesophageal Reflux Disease
Primary: Patient's Assessment of Stanford Sleepiness Scale for the Last 24 Hours (Diaries) — 2.94; 2.62; 2.28; 2.03 Units on a scale
Aortic Aneurysm, Thoracic
Primary: Freedom From Major Adverse Events and Major Device Events Through 1 Year Post-treatment — 11 Participants
Migraine
Primary: Pain Relief at 2 Hours — 52; 5; 9; 8 Participants — p=0.015
Type 2 Diabetes Mellitus
Primary: Change From Baseline to 48 Week Endpoint in Hemoglobin A1c (HbA1c) — -1.91; -1.87 percent (%) glycated hemoglobin — p=0.716